Pro-Dex, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PDEX research report →
Price Chart
About the company
Pro-Dex, Inc. focuses on the development and manufacturing of advanced motorized surgical instruments. These sophisticated tools are supplied globally to original equipment manufacturers (OEMs) in the medical device sector.
- CEO
- Richard Lee Van Kirk Jr.
- IPO
- 1986
- Employees
- 204
- HQ
- Irvine, CA, US
Get TickerSpark's AI analysis on PDEX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $207.27M
- P/E
- 15.38
- Fwd P/E
- 21.01
- PEG
- 0.29
- P/S
- 2.67
- P/B
- 4.40
- EV/EBITDA
- 10.88
- Div Yield
- 0.00%
- Gross Margin
- 31.38%
- Op Margin
- 16.75%
- Net Margin
- 17.62%
- ROE
- 31.05%
- ROIC
- 14.99%
Latest fiscal year · YoY change
- Revenue
- $77.55M+16.5%
- Gross Profit
- $24.34M+24.7%
- Op Income
- $12.99M
- Net Income
- $13.66M+52.2%
- EPS
- $4.24+55.3%
- OCF Growth
- +530.6%
- FCF Growth
- +330.8%
- 52W High
- $77.00
- 52W Low
- $23.47
- 50D MA
- $65.96
- 200D MA
- $54.70
- Beta
- 0.06
- RSI (14)
- 45
- Avg Volume
- 80.99K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Pro-Dex posted modest year-over-year sales growth in fiscal Q1, but lower-margin mix and higher operating expenses drove a net loss despite improving cash flow and a brighter outlook for product shipments and a new engineering services line.· November 13, 2014
- Net sales rose 2% year over year to $2.6 million, helped by resumed shipments to the largest customer.
- Gross profit fell 12% to $828,000 and gross margin declined to 32% from 37% because the mix shifted away from higher-margin repair revenue.
- Operating expenses increased 10% to $1 million, mainly from business development and project-related legal costs.
- Net loss was $170,000, or $0.04 per share, versus net income of $212,000, or $0.06 per share, last year; prior-year results included a $167,000 gain on a facility sale.
- Management said product shipments from final-stage development projects are still expected within the current fiscal year, and it launched a new Engineering Services Division.
Net sales for the fiscal first quarter ended September 30, 2014 were $2.6 million, up 2% from $2.5 million a year earlier. Gross profit was $828,000, down 12% from $945,000, and gross margin was 32% versus 37% in the prior-year quarter. Operating expenses rose 10% to $1 million from $924,000. Loss from continuing operations was $181,000, versus income from continuing operations of $18,000 last year. Net loss was $170,000, or $0.04 per share, compared with net income of $212,000, or $0.06 per share, in the prior-year period, which included a $167,000 gain on sale of the former Carson City facility. For the outlook, management expects to enter the manufacturing and product shipment phase for development projects within this fiscal year and said additional product sales could begin when those projects commercialize later in the current fiscal year.
CEO Harold Hurwitz emphasized that the apparent earnings weakness was mostly about comparison effects: last year’s quarter had unusually high repair revenue after the largest customer had suspended orders, while this year’s mix was more typical and less profitable. He said he prefers the current setup because product shipments to the largest customer have resumed and follow-on frame contracts have been received. He also pointed to the final testing phase of development projects, the expectation of shipments within the fiscal year, and the launch of the Engineering Services Division as signs of future growth.
The financial story centered on revenue mix and margin pressure. Gross profit fell $117,000 because of lower volumes of high-margin repairs, more lower-margin product sales, accruals for anticipated losses on fixed-price product development services, and under-absorbed manufacturing costs; these were partially offset by lower inventory and warranty charges. Operating expenses increased by $76,000, or 10%, mainly due to business development expenses and project-related legal costs. Management also highlighted that operating cash flow has been positive for the third consecutive quarter, with $840,000 generated over the past three quarters, and noted no tax issues with net operating losses; it also said about 41,000 shares had been repurchased so far under an approved board plan.
In Q&A, the main analyst-style question was about the timing of product development projects. Management said it remains in the final phase of testing and still expects to move into manufacturing and product shipments within the current fiscal year. Questions also covered share repurchases, where management said just over 41,000 shares had been bought back and that the current repurchase plan is not for the full $750,000 board-approved amount. On the new Engineering Services Division, management said it should be additive and synergistic, with potential to help both consulting/placement revenue and business development.
The call suggested that Pro-Dex’s customer relationships are improving, with shipments to the largest customer resumed and follow-on frame contracts in hand. Management also sounded confident that development projects are nearing commercialization, and that could bring additional product sales later in the fiscal year. Positive operating cash flow over three straight quarters and the launch of the Engineering Services Division add to the growth narrative.
Margins remain pressured by a shift away from higher-margin repair work and by costs tied to fixed-price development services and lower manufacturing volumes. Operating expenses are rising, and the company posted a net loss this quarter. Management’s growth thesis still depends on final testing finishing on time and commercialization happening later in the fiscal year, which leaves execution risk.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 54.2%
- Shares Outstanding
- 3.19M
- Float Shares
- 1.73M
of shares held by institutions
58 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 153.18K | ▲ 663 |
| Vanguard Group Inc | 144.57K | ▼ 1.57K |
| Vanguard Capital Management LLC | 82.28K | ▼ 29.05K |
| Dimensional Fund Advisors LP | 57.06K | ▲ 120 |
| Punch & Associates Investment Management, Inc. | 52.73K | ▼ 9.00K |
| Geode Capital Management, LLC | 49.64K | ▲ 1.29K |
| Jpmorgan Chase & Co | 32.29K | ▲ 251 |
| State Street Corp | 31.31K | ▼ 1.80K |
| Goldman Sachs Group Inc | 18.71K | ▲ 8.57K |
| Pekin Hardy Strauss, Inc. | 16.50K | ▲ 16.50K |
| Bnp Paribas Arbitrage, Snc | 15.95K | ▲ 2.71K |
| Northern Trust Corp | 15.62K | ▼ 31.08K |
Held by 93 ETFs
Biggest fund positions in PDEX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 11, 26 | Van Kirk Richard Lee Jr | sell | 290 |
| Sep 11, 26 | Van Kirk Richard Lee Jr | sell | 475 |
| Sep 9, 26 | Van Kirk Richard Lee Jr | sell | 2,160 |
| Sep 9, 26 | Van Kirk Richard Lee Jr | sell | 2,691 |
| Sep 9, 26 | Van Kirk Richard Lee Jr | sell | 4,274 |
| Sep 9, 26 | Van Kirk Richard Lee Jr | sell | 1,157 |
| Sep 9, 26 | Van Kirk Richard Lee Jr | sell | 935 |
| Sep 9, 26 | Van Kirk Richard Lee Jr | sell | 2,144 |
| Sep 9, 26 | Van Kirk Richard Lee Jr | sell | 300 |
| Sep 9, 26 | Van Kirk Richard Lee Jr | sell | 806 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PDEX coverage
Recent articles, reports, and earnings notes.
No research on PDEX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PDEX report →5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve
zacks.com · Oct 1
Best Momentum Stocks to Buy for September 18th
zacks.com · Sep 18
New Strong Buy Stocks for September 18th
zacks.com · Sep 18
Bank of New York Mellon Corp Invests $678,000 in Pro-Dex, Inc. $PDEX
defenseworld.net · Sep 12
Pro-Dex: Still A Buy, But Don't Chase
seekingalpha.com · May 15
Pro-Dex, Inc. Announces Fiscal 2026 Third Quarter and Nine Month Results
accessnewswire.com · Apr 30
Pro-Dex (NASDAQ:PDEX) Stock Price Passes Above 200 Day Moving Average – Should You Sell?
defenseworld.net · Mar 28
Pro-Dex, Inc. Announces Acquisition of Advanced Precision Machining
accessnewswire.com · Feb 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.